Analysis of the results of optical coherence tomography to assess the effectiveness and safety of implantable bioresorbable stenting frames in the long term

Objective: to evaluate the effectiveness and safety of implantation of everolimus-coated bioabsorbable vascular scaffolds (BSCs) based on the results of optical coherence tomography (OCT) in patients with coronary artery disease who have previously undergone percutaneous coronary intervention (PCI). Materials and methods: OCT data from 23 patients with coronary artery disease (CAD) were studied 10 years or more after intervention with BVS implantation. Standard criteria based on OCT analysis were used to evaluate the efficacy of BVS. The stented segment, proximal zone before the stent, and distal zone after the stent were the areas of interest. Results: in the long-term period, the structure of the artery in the area of the installed biodegradable scaffolds is a combination of fragments of an atherosclerotic plaque, a resorbed scaffold, and neointima. When visualized using coherence tomography, this structure appears as a monolayer with high signal intensity. In 42.3% of patients, structures similar to fragments of the stenting frame were visualized, but smaller in size, with a disconnected structure, without clear contours and the absence of a typical shape. In 15.4% of cases, pronounced positive remodeling of the coronary artery in the area of the installation of the bioresorbable frame was noted. Conclusions: analysis of coherence tomography data showed that the use of biodegradable frames is effective and safe, the process of degradation of the frames occurs with an increase in diameter in the stented zone and the formation of a protective monolayer, while maintaining the patency of all side branches in the implantation zone.

1. Jia S, Liu Y, Yuan J. Evidence in Guidelines for Treatment of Coronary Artery Disease. Adv Exp Med Biol. 2020;1177:37-73. DOI: 10.1007/978-981-15-2517-9_2

2. Nathan A, Kobayashi T, Kolansky DM, Wilensky RL, Giri J. Bioresorbable Scaffolds for Coronary Artery Disease. Curr Cardiol Rep. 2017;19(1):5. DOI: 10.1007/s11886-017-0812-7

3. Iannaccone M, D’Ascenzo F, Templin C, Omedè P, Montefusco A, Guagliumi G, et al. Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis. Eur Heart J Cardiovasc Imaging. 2017;18(2):159-166. DOI: 10.1093/ehjci/jew070

4. Cassese S, Byrne RA, Jüni P, Wykrzykowska JJ, Puricel S, Ndrepepa G, et al. Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. EuroIntervention. 2018;13(13):1565-1573. DOI: 10.4244/EIJ-D-17-00492

5. Mahmoud AN, Barakat AF, Elgendy AY, Schneibel E, Mentias A, Abuzaid A, et al. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials. Circ Cardiovasc Interv. 2017;10(5):e005286. DOI: 10.1161/CIRCINTERVENTIONS.117.005286

6. Ali ZA, Serruys PW, Kimura T, Gao R, Ellis SG, Kereiakes DJ, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017;390(10096):760-772. DOI: 10.1016/S0140-6736(17)31470-8

7. Zhang XL, Zhu L, Wei ZH, Zhu QQ, Qiao JZ, Dai Q, et al. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):752-763. DOI: 10.7326/M16-0006

8. Korobka V.L., Khripun A.V., Malevannyy M.V., Kulikovskikh Ya.V. The short-term and mid-term outcomes of percutaneous coronary intervention with implantation of bioresorbable vascular scaffolds for stemi treatment. Russian journal of endovascular surgery. 2015;2(1-2):58-68. eLIBRARY ID: 27640351 EDN: XGWEYF

9. Gori T, Munzel T. First evidence of complete resorption 4 years after bioresorbable scaffold implantation in the setting of ST- segment elevation myocardial infarction. J Am Coll Cardiol Intv. 2017;10(2):200–202.

10. Karanasos A, Simsek C, Gnanadesigan M, van Ditzhuijzen NS, Freire R, Dijkstra J, et al. OCT assessment of the long-term vascular healing response 5 years after everolimus-eluting bioresorbable vascular scaffold. J Am Coll Cardiol. 2014;64(22):2343-2356. DOI: 10.1016/j.jacc.2014.09.029

11. Zhang XL, Zhu L, Wei ZH, Zhu QQ, Qiao JZ, Dai Q, et al. Comparative Efficacy and Safety of Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents: A Systematic Review and Meta-analysis. Ann Intern Med. 2016;164(11):752-763. DOI: 10.7326/M16-0006

12. García-García HM, Muramatsu T, Nakatani S, Lee IS, Holm NR, Thuesen L, et al. Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study. Eur Heart J Cardiovasc Imaging. 2014;15(9):987-995. DOI: 10.1093/ehjci/jeu042

13. Kochman J, Kołtowski Ł, Tomaniak M, Jąkała J, Proniewska K, Legutko J, et al. First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation Absorb bioresorbable vascular scaffold. EuroIntervention. 2018;13(18):e2201-e2209. DOI: 10.4244/EIJ-D-17-00311

14. Strandberg E, Zeltinger J, Schulz DG, Kaluza GL. Late positive remodeling and late lumen gain contribute to vascular restoration by a non-drug eluting bioresorbable scaffold: a fouryear intravascular ultrasound study in normal porcine coronary arteries. Circ Cardiovasc Interv. 2012;5(1):39-46. DOI: 10.1161/CIRCINTERVENTIONS.111.964270

15. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9(11):1271-1284. DOI: 10.4244/EIJV9I11A217